ORDER (1) GRANTING DEFENDANTS’ MOTION TO DISMISS DIRECT PURCHASER’S COMPLAINT AND (2) GRANTING IN PART AND DENYING IN PART ALZA’S MOTION TO DISMISS INDIRECT PURCHASERS’ COMPLAINT
Now before the Court are Defendants’ motions to dismiss the two consolidated class action complaints filed by plaintiff American Sales Company (“ASC” or “Direct Purchaser Plaintiff’)
1
and by City of
BACKGROUND
This is an antitrust action. In essence, the Direct and Indirect Purchaser Plaintiffs allege that Defendants filed a baseless complaint to preclude a competitor from producing a generic version of the drug Ditropan XL, as well as other anti-competitive conduct. They further allege that through such anti-competitive conduct, Alza was able to maintain a monopoly and charge supra-competitive prices for Ditro-pan XL. According to the Direct and Indirect Purchaser Plaintiffs, Defendants’ conduct in delaying or preventing the sale of a generic version of the drug caused them to pay more than they otherwise -would have paid for the drug.
Direct Purchaser Plaintiff brings the following two claims: (1) a claim premised on Section 2 of the Sherman Act and (2) a claim for restitution, disgorgement and constructive trust. Indirect Purchaser Plaintiffs assert the following three claims: (1) a claim under the California Cartwright Act; (2) a claim for violation of California Business and Professions Code section 17200; and (3) a claim for violation of the antitrust statutes of twenty-eight different states — Alabama, Alaska, Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, Vermont, West Virginia, and Wisconsin.
The Court will address additional specific facts as required in the analysis.
ANALYSIS
A. Direct Purchaser Plaintiffs Complaint.
1. Antitrust Claim.
Admittedly, Direct Purchaser Plaintiff did not purchase Ditropan XL from Alza or Johnson & Johnson. Rather, Direct Purchaser Plaintiffs claims are premised on Cardinal Health, Incorporated’s (“Cardinal”) purchases of Ditropan XL from Ortho-McNeil Pharmaceutical, Incorporated (“Ortho-McNeil”), a wholly owned subsidiary of Johnson & Johnson. Direct Purchaser Plaintiff asserts that Cardinal purportedly assigned its antitrust claims to it. (Declaration of Michael A. Sitzman (“Sitzman Deck”), Ex. 1.) It is undisputed that Direct Purchaser Plaintiff did not directly purchase Ditropan XL from Defendants and that its ability, if any, to maintain a direct purchaser action against Defendants, arises out of its purported assignment from Cardinal. However, Direct Purchaser Plaintiffs complaint fails to allege the existence of the assignment from Cardinal. Without such allegations, any antitrust claims by Direct Purchaser Plaintiff are insufficient. Accordingly, the Court dismisses the Direct
2. Unjust Enrichment.
At the hearing on Defendants’ motion to dismiss, Direct Purchaser Plaintiff clarified that its unjust enrichment claim is based on state law, but it has not plead under which state or states laws it is based. In fact, Direct Purchaser Plaintiff admitted it is not yet aware of which state or states’ laws it is moving under. Its ability to plead a claim for unjust enrichment may vary from state to state, and unless and until Direct Purchaser Plaintiff clarifies under what state law it is moving, neither Defendants nor the Court can address whether the claim or claims have been adequately plead. Accordingly, the Court dismisses the unjust enrichment claim without prejudice.
B. Indirect Purchaser Plaintiffs’ Complaint.
Indirect Purchaser Plaintiffs concede they are not bringing an antitrust claim under New Jersey law. (Indirect Purchasers’ Opp. at 13.) Accordingly, the Court grants Alza’s motion as to the New Jersey antitrust claim.
1. Unfair Competition Law Claim.
Alza moves to dismiss Indirect Purchaser Plaintiffs’ unfair competition law claim under California Business and Professions Code § 17200 (“UCL”) on the following grounds: (1) the remedy Indirect Purchaser Plaintiffs seek is precluded under the UCL and (2) Indirect Purchaser Plaintiffs failed to allege reliance. 3
Damages cannot be recovered pursuant to a UCL claim.
Korea Supply Co. v. Lockheed Martin Corp.,
In support of its argument, Alza relies primarily on language from the California Supreme Court opinion in
Korea Supply.
In
Korea Supply,
the court addressed when disgorgement of a defendant’s profits qualifies as restitution and, thus, is recoverable under UCL claims.
Korea Supply,
In
Korea Supply,
a plaintiff who alleged a lost business opportunity due to the unfair practices of a competitor sought to obtain disgorgement of the competitor’s profits.
Korea Supply,
The court reasoned that “[t]he object of restitution is to restore the status quo by returning to the plaintiff funds in which he or she has an ownership interest.”
Id
at 1149,
Alza places great weight on the word “directly” in the preceding sentence, and argues that because Plaintiffs, as indirect purchasers, did not pay any money
directly
to Alza, Plaintiffs cannot recover restitution under the UCL. However, as noted above, it was clear in
Korea Supply
that the plaintiff did not pay
any
money, even indirectly, to the defendant. In
Korea Supply,
the defendant’s conduct merely caused the plaintiff to lose an opportunity to obtain a commission it would have received if a third party had awarded a contract to its client. Although the court mentions that “direct victims” of unfair competition may obtain restitution,
id.
at 1152,
Nor do the other cases relied on by Alza convince the Court that Indirect Purchaser Plaintiffs are precluded from recovering restitution as a matter of law.
See Madrid v. Perot Systems Corp.,
Alza’s reliance on
In re First Alliance Mortgage Co.,
[T]he [plaintiffs] in this case cast their claim under section 17200 as one for equitable relief by asking the court to disgorge [the defendant’s] “ill-gotten gains,” asserting that [the defendant] unlawfully acquired money and property directly and indirectly from the [plaintiffs] and has been unjustly enriched at théir expense. They do not, however, specify the amount of these “ill-gotten gains” to which they have an actual ownership interest.
Id. at 997. Significantly, the plaintiffs “did not actually claim an' ownership interest in funds in [the defendant’s] possession, nor explain the basis of their purported ownership interest in those funds.” Id. at 997 n. 7. Therefore, the court found that their equitable claim under the UCL would be left largely to the court’s speculation and thus, affirmed summary judgment against the plaintiffs. Id. at 997-98. In contrast, Indirect Purchaser Plaintiffs here do allege an ownership interest in funds received by Alza, namely, the profits Alza obtained by allegedly inflating the price of Ditropan XL.
Although the parties did not cite to, and the Court did not find, any authority applying California law that squarely addresses whether
indirect
purchaser plaintiffs may recover restitution under the UCL,
5
the Court notes that one district court refused to dismiss a UCL claim in a factually analogous situation.
See Trew v. Volvo Cars of North America, LLC,
In light of the reasoning of Korea Supply, as well as that of Trew, the Court concludes that as long as Indirect Purchaser Plaintiffs are ultimately able to prove traceability, California law authorizes this Court to award them restitution under the UCL. Indirect Purchaser Plaintiffs are seeking to recover funds that they overpaid to Alza. 6 That Indirect Purchaser Plaintiffs allege such funds were paid to Alza through an intermediary does not change the fact that Indirect Purchaser Plaintiffs are seeking funds in which they have an ownership interest. If Indirect Purchaser Plaintiffs can demonstrate that the amount they overpaid for Ditropan XL was the amount that Alza overcharged, and that any intermediaries merely passed on the overcharge from Alza to the Indirect Purchaser Plaintiffs as end-paying customers, they may recover such funds as restitution under the UCL.
ii. Plaintiffs Need Not Allege Reliance.
Alza also argues that Indirect Purchaser Plaintiffs UCL claim should be dismissed because they have not alleged reliance on any misrepresentations. Pursuant Section 17200, “there are three varieties of unfair competition: practices which are unlawful, unfair or fraudulent.”
See Daugherty v. American Honda Motor Co., Inc., 144
Cal.App.4th 824, 837,
Proposition 64, which was approved by California voters on November 2, 2004, amended the UCL to limit the standing of private plaintiffs to bring UCL claims to those who “suffered injury in fact and has lost money as a result of such unfair competition.”
Laster v. T-Mobile USA, Inc.,
In Laster, the plaintiffs’ UCL claim was brought under the fraudulent prong of Section 17200 and was premised on alleged false advertising by a phone company. According to the plaintiffs, the phone company falsely advertised that cell phones were free or substantially discounted but charged customers sales tax based on the phones’ full retail value. Id. at 1194. However, the plaintiffs failed to allege that they actually relied on any false or misleading advertising in entering into the transactions and, thus, failed to adequately allege causation. Id.
Similarly, in
Texaco,
the plaintiffs’ UCL claim was based on alleged misrepresentations.
Texaco,
It is logical to require reliance on misrepresentations when a UCL claim is premised on allegations that the defendants engaged in fraudulent business practices. However, where, as here, plaintiffs allege that they were harmed by other types of misconduct actionable under the UCL the Court finds no basis for requiring reliance on misrepresentations.
In essence, Indirect Purchaser Plaintiffs allege that Alza filed a baseless complaint to preclude a competitor from producing a generic version of Ditropan XL, as well as other anticompetitive conduct. (Indirect Purchaser Compl., ¶¶ 92-98.) They further allege that through such anti-competitive conduct, Alza was able to maintain a monopoly and charge supra-competitive prices. (Id., ¶ 246.) According to Indirect Purchaser Plaintiffs, Alza’s conduct in delaying or preventing the sale of a generic version caused them to pay more than they otherwise would have for the drug. (Id., ¶ 251.) Thus, at the very least, they allege a UCL claim premised on the unfair prong. Because Indirect Purchaser Plaintiffs have alleged facts sufficient to state a claim under the unfair prong, the Court need not determine on a motion to dismiss whether they have also alleged sufficient facts to maintain then- UCL claim under the fraudulent prong.
3. Standing To Bring Various Antitrust State Law Claims
Except for the antitrust claims based on Tennessee, New York, North Dakota, and New Jersey law, Alza moves to dismiss all of Indirect Purchaser Plaintiffs’ state law antitrust claims brought under their third cause of action on the grounds of lack of standing. Under their third cause of action, in addition to the antitrust claims based on Tennessee, New York, North Dakota, and New Jersey law, Indirect Purchaser Plaintiffs allege that Alza’s conduct violates the antitrust laws of the following twenty-four states: Alabama, Alaska, Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Mexico, North Carolina, South Dakota, Vermont,
To demonstrate standing “named plaintiffs who represent a class must allege and show that they personally have been injured, not that injury has been suffered by other, unidentified members of the class to which they belong and which they purport to represent.”
Lewis v. Casey,
Indirect Purchaser Plaintiffs do not assert there is basis to confer standing on them to bring claims based on the state law of states in which they do not reside, but rather, argue that the determination of standing is premature prior to class certification. (Indirect Purchasers’ Opp. at 11-12) (citing
Ortiz v. Fibreboard Corp.,
Plaintiffs bear the burden of demonstrating standing.
Lujan v. Defenders of Wildlife,
4. Donnelly Act.
Alza moves to dismiss Indirect Purchaser Plaintiffs’ claim under New York General Business Law § 340, known as the “Donnelly Act,” which is New York’s antitrust statute.
See Leider v. Ralfe,
387
New York Civil Practice Law and Rules § 901 (“CPLR 901”), which sets forth the prerequisites to class action suits, provides in pertinent part that “[u]nless a statute creating or imposing a penalty, or a minimum measure of recovery specifically authorizes the recovery thereof in a class action, an action to recover a penalty, or minimum measure of recovery created or imposed by statute may not be maintained as a class action.” N.Y. C.P.L.R. § 901(b). The Donnelly Act in turn provides in pertinent part: “any person who shall sustain damages by reason of any violation of this section,
shall recover three-fold the actual damages
sustained thereby....” N.Y. Gen. Bus. Law § 840(5) (emphasis added). The statute is silent as to class actions. Cases applying New York law have construed the Donnelly Act in light of CPLR 901 and, thus, have held that class actions cannot be maintained under the Donnelly Act.
See Leider,
In opposition to the motion to dismiss, Indirect Purchaser Plaintiffs argue that Alza “ignores the New York Supreme Court’s Appellate Division holding entitling a plaintiff to bring a class action for antitrust activities pursuant to N.Y. Gen. Bus. Law § 349 if the plaintiff foregoes any demand for punitive damages.” (Indirect Purchasers’ Opp. at 15.) In support of them argument, they cite to
Cox v. Microsoft Corp.,
5. Tennessee Law.
Indirect Purchaser Plaintiffs plead an antitrust claim under Tennessee Trade Practices Act, TenmCode Ann. § 47-25-101 et seq. (“TTPA”). Alza moves to dismiss this claim on the basis that Indirect Purchaser Plaintiffs complaint only pleads unilateral conduct, which is not covered by the TTPA. The TTPA prohibits “all arrangements, contracts, agreements, trusts, or combinations between persons or corporations designed, or which tend, to advance, reduce, or control the price or the cost to the producer or the consumer of any such product or article.” See Tenn. Code Ann. § 47-25-101 (emphasis added).
The only authority cited by the parties analyzing the language of the TTPA and whether it applies to unilateral conduct is
In re Relajen Antitrust Litig.,
221 F.R.D.
In their brief in opposition to the motion to dismiss and at the hearing, Indirect Purchaser Plaintiffs rely on the plain language of the TTPA to argue that the statute encompasses Alza’s conduct as alleged in their complaint. At the hearing, they argued that the language “all arrangements” is broad. However, they ignore the modifying language “between persons or corporations.” The cases cited to by Indirect Purchaser Plaintiffs at the hearing do not assist them because those cases did not address whether a defendant’s unilateral activity to exclude competitors from the market would be prohibited by the TTPA.
See In re Cardizem CD Antitrust Litig.,
Upon review of the plain language of the Tennessee statute, and in the absence of any authority demonstrating that Tennessee courts would construe this language to apply to the conduct alleged in this action, the Court finds that the TTPA does not encompass the conduct the Indirect Purchaser Plaintiffs have alleged. Accordingly, the Court grants Alza’s motion to dismiss as to Plaintiffs antitrust claim under Tennessee law. This ruling is without prejudice to Indirect Purchaser Plaintiffs’ seeking leave to amend if they are aware of additional facts they could allege which would be sufficient to demonstrate covered conduct between persons or corporations.
CONCLUSION
For the foregoing reasons, the Court ORDERS as follows:
(1) Defendants’ motion to dismiss Direct Purchaser Plaintiffs complaint is GRANTED; (2) Alza’s motion to dismiss Indirect Purchaser Plaintiffs’ complaint is GRANTED as to their claims under the antitrust laws of New Jersey, New York, Tennessee, Alabama, Alaska, Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan Minnesota, Mississippi, Nebraska, Nevada, New Mexico, North Carolina, South Dakota, Vermont, West Virginia, and Wisconsin; and (3) Alza’s motion to dismiss Indirect Purchas
This ruling is without prejudice to Direct and Indirect Purchaser Plaintiffs filing amended complaints in compliance with this Order. Direct and Indirect Purchaser Plaintiffs shall file any amended complaints within twenty-one days of the date of this Order. If Direct Purchaser Plaintiffs do not file an amended complaint within twenty-one days, its action shall be dismissed. If necessary, Defendants shall file their answers or move to dismiss within twenty days of service of any amended complaint or the deadline to amend has expired, whichever is earlier.
IT IS SO ORDERED
Notes
. Although the Direct Purchaser Plaintiff class action complaint was filed by Stephen L. LaF-rance Holdings ("LaFrance”) and SAJ Distributors ("SAJ”) as well, LaFrance and SAJ recently submitted a notice of voluntary dismissal. (Docket No. 60.)
. The Court notes that Direct Purchaser Plaintiff's complaint may suffer from another defect. Direct Purchaser Plaintiff does not dispute that neither Alza nor Johnson & Johnson sold Ditropan XL during the class period. Rather, its antitrust claim against these defendants is premised on the sales by Ortho-McNeil. In response to the Court's concern regarding the validity of a direct purchaser action that fails to name the direct seller, Direct Purchaser Plaintiff cited to
Illinois Brick Co. v. Illinois,
. Even though Alza did not move to dismiss Indirect Purchaser Plaintiffs’ UCL claim on the grounds of lack of standing, the Court questioned Alza at the hearing on its motion as to whether its standing argument would apply to this claim as well. In response, Alza argued it would. However, non-California resident plaintiffs may bring a UCL claim based on misconduct that occurs within the California.
Norwest Mortgage, Inc. v. Superior Court,
. The Court grants Alza's request for leave to submit this decision.
. Both parties assert that
Colgan,
. The Court notes that Defendants contend Ortho-McNeil, not Alza, sold Ditropan XL during the class period. If true, Plaintiffs may be precluded from seeking any restitution because the money they are seeking to recover was not actually paid to Alza. Indirect Purchaser Plaintiffs may need to proffer the existence of facts and authority demonstrating that the money paid to Ortho-McNeil may be attributed to Alza for purposes of the UCL claim and that Ortho-McNeil should not be considered a separate entity. However, because Alza did not raise this point in its motion, and because the facts upon which the Court could decide this issue are not yet before it, the Court declines to dismiss Indirect Purchaser Plaintiffs' UCL claim at this stage.
. The Court notes that Indirect Purchaser Plaintiffs allege a claim under California’s antitrust law, the Cartwright Act, under both their second and third causes of action. Although Alza only raised its standing argument with respect to Plaintiffs’ Cartwright Act claim under the third cause of action, the Court's finding that Plaintiffs failed to demonstrate standing as to this claim necessarily applies to the same claim pled under the second cause of action. Accordingly, the Court need not address the parties' arguments as to whether Indirect Purchaser Plaintiffs sufficiently alleged coercive conduct actionable under the Cartwright Act.
